Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. April 2004 16:38 ET | Quelle: CytoGenix, Inc.

CytoGenix, Inc. Anti-Sepsis Compound Works in Mice, Files U.S. Patent Application

HOUSTON, April 6, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTCBB:CYGX) announces the filing of a patent application with the U.S. Patent and Trademark Office for an invention titled Oligodeoxynucleotide...
10. März 2004 09:45 ET | Quelle: CytoGenix, Inc.

CytoGenix Awarded National Cancer Institute Research Grant for Pre-Clinical Animal Trials of Aerosol Delivered Gene Silencing Agent Against Lung Tumors

HOUSTON, March 10, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTCBB:CYGX) announced that the National Cancer Institute (NCI) has awarded the company a research grant to fund the first phase of a project...
09. März 2004 15:43 ET | Quelle: CytoGenix, Inc.

CytoGenix Awarded National Cancer Institute Research Grant for Pre-Clinical Animal Trials of Aerosol Delivered Gene Silencing Agent against Lung Tumors

HOUSTON, March 9, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTCBB:CYGX) announced that the National Cancer Institute (NCI) has awarded the company a research grant to fund the first phase of a project...
02. März 2004 17:01 ET | Quelle: CytoGenix, Inc.

CytoGenix Announces Results of Anti-Sepsis Pre-Clinical Animal Trials

HOUSTON, March 2, 2004 (PRIMEZONE) -- CytoGenix, Inc. (OTCBB:CYGX) announced the successful completion of the first phase of pre-clinical animal studies. These proof-of-concept studies show that the...